Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix to Present Corporate Overview at the Barclays Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , March 09, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix to Present Corporate Overview at the 28th Annual ROTH Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , March 07, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Reports Fiscal Year 2015 Financial Results and Provides Business Update
Conference Call and Webcast Today at 8:00am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , March 03, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing
Toggle Summary Foamix to Present Corporate Overview at the 36th Annual Cowen & Company Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 29, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call & Webcast Scheduled for Thursday, March 3
REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 18, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Announces Positive Results From Phase 1 Study to Characterize Minocycline Bioavailability of FMX-101 Compared to Solodyn® (Minocycline HCl) Extended-Release Tablets
Minocycline Systemic Bioavailability For FMX-101 Was More Than 100 Times Lower Than That For Solodyn. FMX-101 Was Well-Tolerated. REHOVOT, Israel and BRIDGEWATER, N.J. , Jan. 07, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix”), a clinical stage specialty pharmaceutical
Toggle Summary Foamix to Present Corporate Overview at the 3rd Annual Dermatology Summit Meeting
REHOVOT, Israel and BRIDGEWATER, N.J. , Jan. 04, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr.
Toggle Summary Foamix Announces Positive Top-Line Results From Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers
Conference Call and Webcast Today, December 3rd @ 8:30am Eastern Time FDX104 prevented the development of moderate-to-severe antibody-induced rash in the majority of cases. FDX104 appears safe and was well-tolerated. REHOVOT, Israel and BRIDGEWATER, N.J. , Dec.
Toggle Summary Foamix to Host Conference Call & Webcast to Discuss Topline Results From Phase 2 Study of FDX-104 in Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers
Conference Call and Webcast on Thursday, December 3rd @ 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , Dec. 2, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing
Toggle Summary Foamix to Present Corporate Overview at the Oppenheimer 26th Annual Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , Dec. 1, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix to Present Corporate Overview at Jefferies Autumn 2015 Global Healthcare Conference in London
REHOVOT, Israel and BRIDGEWATER, N.J. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Reports Third Quarter 2015 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, November 11, 2015 at 8:00am Eastern / 5:00am Pacific REHOVOT, Israel , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, November 11
REHOVOT, Israel , and BRIDGEWATER, N.J. , Oct. 27, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea
REHOVOT, Israel and BRIDGEWATER, N.J. , Oct. 20, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Reports Second Quarter 2015 Financial Results and Provides Business Update
Conference Call and Webcast on Thursday, August 20, 2015 at 8:00am Eastern / 5:00am Pacific REHOVOT, Israel , Aug. 19, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and
Toggle Summary Foamix Pharmaceuticals Second Quarter 2015 Conference Call & Webcast Scheduled for Thursday, August 20
REHOVOT, Israel and BRIDGEWATER, N.J. , Aug. 13, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea
REHOVOT, Israel and RALEIGH, N.C. , July 31, 2015 (GLOBE NEWSWIRE) -- As announced today by Bayer HealthCare , the U.S. Food & Drug Administration ( FDA ) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Toggle Summary Foamix Receives Milestone Payment From Merz North America
REHOVOT, Israel and RALEIGH, N.C. , June 16, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals (Nasdaq:FOMX) and Merz North America, Inc. , today announced that the first milestone payment related to their unique foam technology development program has been made to Foamix.
Toggle Summary Foamix to Present Corporate Overview at the Jefferies 2015 Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , May 28, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in
Toggle Summary Foamix Reports First Quarter Financial Results
Conference Call Begins on May 13, 2015 at 8:00am Eastern / 5:00am Pacific REHOVOT, Israel , May 12, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX) ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary